LAURA H. CYPHERS

In this study, the authors assessed whether publication of a visual abstract on social media was associated with reader engagement online.
Source: JAMA Online First

This JAMA Patient Page describes the types of nonprescription heartburn medications: antacids, histamine 2 blockers, and proton pump inhibitors.
Source: JAMA Online First

In this Viewpoint, the authors discuss how clinicians can weigh legal risks against risks to patients’ health and lives when providing essential reproductive care.
Source: JAMA Online First

In this Viewpoint, the authors summarize the therapeutic landscape for COVID-19, discuss who is most likely to benefit from treatment, provide an update on managing illness in immunocompromised individuals, and highlight how to improve COVID-19 treatment.
Source: JAMA Online First

This Arts and Medicine feature reviews journalist Polly Morland’s A Fortunate Woman, a 2022 follow-up to John Berger’s classic 1967 A Fortunate Man, detailing changes over 50 years in the rewards and challenges of primary care practice in small-town rural general practice in northern England.
Source: JAMA Online First

This JAMA Guide to Statistics and Methods explains the use of historical controls—persons who had received a specific control treatment in a previous study—when randomizing participants to that control treatment in a subsequent trial may not be practical or ethical.
Source: JAMA Online First

Hereditary transthyretin (ATTRv) amyloidosis is a progressive, disabling, fatal disease caused by extracellular deposits in organs and tissues of misfolded transthyretin variants and wild-type transthyretin protein. The disease has various clinical manifestations, including cardiomyopathy and polyneuropathy. Drugs targeting hepatic messenger RNA (mRNA) can slow the progression of ATTRv polyneuropathy, because the liver produces 90% of the amyloidogenic protein. The specific interaction between the TTR silencer drugs and the TTR mRNA leads to the breakdown of mRNA, preventing the production of the transthyretin protein. TTR gene silencers have become a powerful therapeutic tool for ATTRv polyneuropathy.
Source: JAMA Online First

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary amyloid transthyretin (ATTRv) polyneuropathy at 40 sites in 15 countries, compared with historical controls.
Source: JAMA Online First

The number of medication errors related to drugs for attention-deficit/hyperactivity disorder (ADHD) in children younger than 20 years reported to US poison centers increased almost 300% from 2000 through 2021. More than half of the errors involved children accidentally taking or being given the medication twice, according to an analysis in Pediatrics of nearly 88 000 reports involving ADHD treatments as the first-ranked substance. Other common errors were taking or being given someone else’s medication or using the wrong medication.
Source: JAMA Online First

In this Medical News article, Ida Sim, MD, PhD, a primary care physician and computational precision health expert at the University of California, San Francisco, discusses the ramifications of using AI technologies in patient care.
Source: JAMA Online First